E Chuang1, N Wiener2, P Christos3, R Kessler2, M Cobham2, D Donovan2, G L Goldberg4, T Caputo5, A Doyle6, L Vahdat2, J A Sparano7. 1. Department of Medicine. Electronic address: elc2007@med.cornell.edu. 2. Department of Medicine. 3. Division of Biostatistics and Epidemiology, Department of Public Health, Weill Cornell Medical College, New York, NY. 4. Department of Obstetrics and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. 5. Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY. 6. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD. 7. Department of Medicine and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
BACKGROUND: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. METHODS: Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. RESULTS: Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m(2) on days 1, 8, and 15 plus PLD 30 mg/m(2) given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer. CONCLUSION: Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.
BACKGROUND:Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. METHODS:Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. RESULTS: Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m(2) on days 1, 8, and 15 plus PLD 30 mg/m(2) given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer. CONCLUSION:Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.
Authors: Jennifer A Low; Suparna B Wedam; James J Lee; Arlene W Berman; Adam Brufsky; Sherry X Yang; Marianne S Poruchynsky; Seth M Steinberg; Nitin Mannan; Tito Fojo; Sandra M Swain Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Sridhar Mani; Hayley McDaid; Anne Hamilton; Howard Hochster; Marvin B Cohen; Dineo Khabelle; Tom Griffin; David E Lebwohl; Leonard Liebes; Franco Muggia; Susan Band Horwitz Journal: Clin Cancer Res Date: 2004-02-15 Impact factor: 12.531
Authors: Owen A O'Connor; Carol Portlock; Craig Moskowitz; David Straus; Paul Hamlin; Michael Stubblefield; Otila Dumetrescu; A Dimitrios Colevas; Barbara Grant; Andrew Zelenetz Journal: Br J Haematol Date: 2008-08-04 Impact factor: 6.998
Authors: Edith A Perez; Guillermo Lerzo; Xavier Pivot; Eva Thomas; Linda Vahdat; Linda Bosserman; Patrice Viens; Can Cai; Brian Mullaney; Ronald Peck; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2007-07-02 Impact factor: 44.544
Authors: Neelima Denduluri; Jennifer A Low; James J Lee; Arlene W Berman; Janice M Walshe; Ujala Vatas; Catherine K Chow; Seth M Steinberg; Sherry X Yang; Sandra M Swain Journal: J Clin Oncol Date: 2007-07-02 Impact factor: 44.544
Authors: Azadeh Kheirolomoom; Matthew T Silvestrini; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Spencer K Tumbale; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; Katherine W Ferrara Journal: J Control Release Date: 2019-04-09 Impact factor: 9.776